← Research library

Retinalamin in diabetic retinopathy: three-month imaging and electrical responses

Comparison in people · 2024

What was studied
56 people with type 1 or type 2 diabetes and retinopathy without active macular edema. Retinalamin and comparison arms each included 28 people (56 eyes).
Main finding
At three months, mean ganglion-cell complex thickness went from 105.45 to 109.14 µm with Retinalamin and from 103.46 to 101.50 µm in controls. The paper reports p = 0.047 for change within the treated group.

Ganglion-cell complex (GCL++) · 105.45 to 109.14 µm at month 3 · 103.46 to 101.50 µm in controls · p = 0.047 for treated group versus baseline

Reported findings and study design

Patients received ten daily intramuscular injections or were followed without Retinalamin. The team used optical coherence tomography (OCT) and pattern and full-field electroretinography (ERG) at baseline, month 1 and month 3.

Population or model 56 people with type 1 or type 2 diabetes and retinopathy without active macular edema. Retinalamin and comparison arms each included 28 people (56 eyes).

Dose, route and schedule

Ten daily intramuscular injections, with assessments at baseline and months 1 and 3. The papers leave the mass per injection unspecified. The earlier paper describes the Diopsys functional assessment in the same clinical groups.

Protocol source ↗ · Companion functional paper, confirmed cohort reuse in the later article

Results · Original article, methods and Tables 1–2
MeasureResultComparison, timing and statistics
Ganglion-cell complex (GCL++)105.45 to 109.14 µm at month 3103.46 to 101.50 µm in controls · p = 0.047 for treated group versus baseline
Full-field ERG magnitude0.77 to 0.87 µV at month 30.91 to 0.88 µV in controls · p = 0.0489 for treated group versus baseline
Ganglion-cell and inner plexiform layers (GCL+)63.69 µm at baseline, 61.55 µm at month 1, 65.79 µm at month 365.04, 64.50 and 63.43 µm in controls
Selected OCT and ERG means by visit
Selected OCT and ERG means by visit
Measure and groupBaselineMonth 1Month 3Month 3 vs baseline
GCL++ (µm), Retinalamin105.45106.76109.14p = 0.047
GCL++ (µm), comparison103.46102.81101.50p unspecified
Nerve fiber layer (µm), Retinalamin41.6643.1043.41p = 0.048
Nerve fiber layer (µm), comparison38.4338.3138.07p unspecified
Pattern ERG magnitude at 100% (µV), Retinalamin0.981.201.18p = 0.028
Pattern ERG magnitude at 100% (µV), comparison1.271.261.26p unspecified
Full-field ERG magnitude (µV), Retinalamin0.770.850.87p = 0.0489
Full-field ERG magnitude (µV), comparison0.910.920.88p unspecified

The publication provides confidence intervals for arm means. The p values shown test change within the Retinalamin arm.

Source for these results ↗ · Reviewed 2026-11-16

Study limitations and source details

Study limitations

  • The authors explicitly reuse the clinical groups from their earlier functional paper. These are two reports on one 56-person cohort.
  • The groups start with different retinal electrical readings. The reported p values compare treated patients with their own baseline. The paper leaves group assignment, masking and the handling of measurements from both eyes unclear.
  • These measures track retinal structure and electrical function. The data leave vision preservation and long-term disease progression unanswered.

Source details

Original journal report

Original Russian full article, Tables 1–2 and companion functional report.

Sources checked

Citation

Published

Human comparative studyFull text available

A. I. Malakhova, V. V. Strakhov, Y. A. Malakhova. Retinalamin in diabetic retinopathy: three-month imaging and electrical responses Vestnik Oftalmologii. 2024;140(5):97–104.

Study source ↗ · DOI 10.17116/oftalma202414005197 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards